{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:12:38Z","timestamp":1778181158965,"version":"3.51.4"},"reference-count":23,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and objectives: To report the initial response to a single intravitreal brolucizumab (IVI-B) injection in wet age-related macular degeneration (wAMD) or polypoidal choroidopathy (PCV) complicated with either persistent subretinal fluid (SRF) or pigment epithelial detachment refractory to previous anti-vascular endothelial growth factor (anti-VEGF) therapy. Material and methods: In this retrospective study, all eyes received a single IVI-B (6 mg\/0.05 mL) for wAMD or PCV with treatment-resistant SRF or PED. Outcome measures included assessment in central retinal thickness (CRT), visual acuity, and evaluation for changes in the SRF or PED on OCT. Follow-up was prior to the first brolucizumab injection, then at 1 week and 5 weeks afterwards. Results: In total, 10 eyes of 10 patients (6 women [60%]) were enrolled. Five patients had wAMD and five patients had PCV. Average age of participants was 67.6 years. All patients received one IVI-B. All patients were not treatment-na\u00efve to anti-VEGF agents. At the first week and fifth week following the first IVI-B, seven out of seven patients (100%) had resolved SRF. However, seven out of nine patients (78%) had no improvement of their PED at 5 weeks follow-up. Mean PED height and width before the first IVI-B was 339.77 \u00b5m and 2233.44 \u00b5m, respectively. Mean PED height and width at the fifthweek following the first IVI-B was 328.125 \u00b5m and 2129.5 \u00b5m, respectively. Overall mean visual acuity before the first IVI-B was 0.224; and 5 weeks following the first IVI-B was 0.38. Conclusions: Treatment with brolucizumab resulted in anatomical improvement for all patients with persistent SRF. Limited efficacy was seen for persistent PED. Brolucizumab appears to be a safe and effective option for treatment-resistant SRF. Future multicenter collaborative studies are warranted.<\/jats:p>","DOI":"10.3390\/medicina58121703","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T02:10:54Z","timestamp":1669169454000},"page":"1703","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2125-9495","authenticated-orcid":false,"given":"Alan Y.","family":"Hsu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, China Medical University Hospital, China Medical University, 2 Yuh-Der Road, Taichung 40447, Taiwan"},{"name":"Department of General Medicine, China Medical University Hospital, Taichung 406040, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Ying","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China Medical University Hospital, China Medical University, 2 Yuh-Der Road, Taichung 40447, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7880-9198","authenticated-orcid":false,"given":"Chun-Ju","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China Medical University Hospital, China Medical University, 2 Yuh-Der Road, Taichung 40447, Taiwan"},{"name":"School of Medicine, College of Medicine, China Medical University, Taichung 406040, Taiwan"},{"name":"Department of Optometry, Asia University, Taichung 413305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Ting","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China Medical University Hospital, China Medical University, 2 Yuh-Der Road, Taichung 40447, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-1316","authenticated-orcid":false,"given":"Ning-Yi","family":"Hsia","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China Medical University Hospital, China Medical University, 2 Yuh-Der Road, Taichung 40447, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane-Ming","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China Medical University Hospital, China Medical University, 2 Yuh-Der Road, Taichung 40447, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9099-3151","authenticated-orcid":false,"given":"Peng-Tai","family":"Tien","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China Medical University Hospital, China Medical University, 2 Yuh-Der Road, Taichung 40447, Taiwan"},{"name":"Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University, Taichung 406040, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping-Ping","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China Medical University Hospital, China Medical University, 2 Yuh-Der Road, Taichung 40447, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ning","family":"Ku","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China Medical University Hospital, China Medical University, 2 Yuh-Der Road, Taichung 40447, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Lu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China Medical University Hospital, China Medical University, 2 Yuh-Der Road, Taichung 40447, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Yu","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, China Medical University Hospital, China Medical University, 2 Yuh-Der Road, Taichung 40447, Taiwan"},{"name":"Department of General Medicine, China Medical University Hospital, Taichung 406040, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/2320-3897.174429","article-title":"Intravitreal injections: A review of pharmacological agents and techniques","volume":"4","author":"Shikari","year":"2016","journal-title":"J. Clin. Ophthalmol. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","article-title":"Fundamental principles of an anti-VEGF treatment regimen: Optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases","volume":"255","author":"Lanzetta","year":"2017","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1358\/dot.2020.56.11.3199812","article-title":"Brolucizumab as treatment of wet age-related maculopathy","volume":"56","author":"Rahman","year":"2020","journal-title":"Drugs Today"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ophtha.2022.04.028","article-title":"MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid","volume":"129","author":"Khanani","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7601","DOI":"10.1073\/pnas.1100223108","article-title":"Mice with behavioral evidence of tinnitus exhibit dorsal cochlear nucleus hyperactivity because of decreased GABAergic inhibition","volume":"108","author":"Middleton","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/IAE.0000000000003418","article-title":"Short-Term Outcomes After Interim Treatment with Brolucizumab: A Retrospective Case Series of a Single Center Experience","volume":"42","author":"Awh","year":"2022","journal-title":"Retina"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Nam, S.W., Byun, Z., Ham, D.-I., and Kong, M. (2022, September 01). Response to Brolucizumab Treatment for Refractory Serous Pigment Epithelial Detachment Secondary to Polypoidal Choroidal Vasculopathy. Available online: https:\/\/www.researchsquare.com\/article\/rs-1693000\/latest.pdf.","DOI":"10.21203\/rs.3.rs-1693000\/v1"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Rispoli, M., Eandi, C.M., Di Antonio, L., Kilian, R., Montesel, A., and Savastano, M.C. (2021). Biomarkers in Early Response to Brolucizumab on Pigment Epithelium Detachment Associated with Exudative Age-Related Macular Degeneration. Biomedicines, 9.","DOI":"10.3390\/biomedicines9060668"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"860784","DOI":"10.3389\/fphar.2022.860784","article-title":"First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration","volume":"13","author":"Abdin","year":"2022","journal-title":"Front. Pharm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/OPTH.S9307","article-title":"Treatment of retinal pigment epithelial detachment with antiangiogenic therapy","volume":"4","author":"Arias","year":"2010","journal-title":"Clin. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.survophthal.2007.02.008","article-title":"Retinal pigment epithelial detachment","volume":"52","author":"Moroz","year":"2007","journal-title":"Surv. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","article-title":"Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: Same or different disease?","volume":"29","author":"Laude","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2013.03.009","article-title":"Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration","volume":"59","author":"Finger","year":"2014","journal-title":"Surv. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2147\/OPTH.S256009","article-title":"Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration","volume":"14","author":"Veluswamy","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1038\/s41598-022-08492-7","article-title":"Evaluation of vascular endothelial growth factor (VEGF) level in the tears and serum of age-related macular degeneration patients","volume":"12","author":"Zunaina","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Eng, V.A., Rayess, N., Nguyen, H.V., and Leng, T. (2020). Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0232353"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/archopht.121.10.1392","article-title":"Polypoidal choroidal vasculopathy: Incidence, demographic features, and clinical characteristics","volume":"121","author":"Sho","year":"2003","journal-title":"Arch. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","article-title":"Clinical characteristics of exudative age-related macular degeneration in Japanese patients","volume":"144","author":"Maruko","year":"2007","journal-title":"Am. J. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/jamaophthalmol.2020.5130","article-title":"Changes in Treatment-Naive Pigment Epithelial Detachments Associated With the Initial Anti-Vascular Endothelial Growth Factor Injection: A Post Hoc Analysis From the HARBOR Trial","volume":"139","author":"Javaheri","year":"2021","journal-title":"JAMA Ophthalmol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/12\/1703\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:24:35Z","timestamp":1760145875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/12\/1703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":23,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["medicina58121703"],"URL":"https:\/\/doi.org\/10.3390\/medicina58121703","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,22]]}}}